Navigation Links
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
Date:12/8/2011

eutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinically active compounds, both of which have demonstrated durable complete responses (CRs) and an overall survival (OS) benefit in Phase I/II studies. SL-401 has completed a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) where it has demonstrated single agent activity, including two durable CRs and an OS benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. SL-401 is also currently being tested in additional indications including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). The Company's second clinical program, SL-701, has demonstrated single agent activity including durable tumor responses, which includes CRs, multiple partial responses (PRs) and an OS benefit, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:
Mark Jacobson
Associate Director, Business Development
Stemline Therapeutics, Inc.
Tel: 212-584-5747
Email: mjacobson@stemline.com

This announcement contains forward-looking statements relating to Stemline's business, which are based on the Company's current expectations concerning future d
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
6. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
7. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
8. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
9. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
10. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... April 6, 2011 Definiens, the number one Health ... specializing in advanced cancer diagnostics, today announced a partnership ... diagnosis of cancer. Cernostics will apply Definiens, image analysis ... treatment of a variety of cancer types. ...
... areas of Virginia, blackbirds are causing moderate to severe crop ... has issued a Section 18 exemption to the standard label ... use Avipel® Crop Seed Treatment to protect their field and ... damage to crops is not unique to this state, and ...
... subsidiary of Eisai Inc., announced today that it was recently ... a national support services organization for people affected by cancer, ... people facing lung and ovarian cancers.  The two organizations have ... aware of options available to help treat and manage these ...
Cached Biology Technology:Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests 2Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests 3Bird Repellent Gains Approval by Virginia 2Morphotek®, Inc. Receives Beacon Award From CancerCare 2Morphotek®, Inc. Receives Beacon Award From CancerCare 3
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... species may be able to cope with the rising salinity ... The Arctic today is best known for its tundra and ... 53 to 38 million years ago during what is known ... a huge temperate forest with brackish water, home to a ... crocodiles and giant tortoises. Much of what is known about ...
(Date:7/9/2014)... a sparrow-sized fossil from China challenges the commonly held ... gained the ability to fly. The birdlike fossil is ... rather the remains of a tiny tree-climbing animal that ... Dinosaur Museum in Blanding, Utah, and Alan Feduccia of ... Springer,s Journal of Ornithology . , The fossil ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... in the FASEB Journal suggests ... role in cell death induced by microgravity environments, and ... lessen the severity of immune problems in astronauts caused ... problems that mimic the aging process on Earth, this ...
... increase the life span of mice with progeria (premature ... dystrophy) by reducing levels of a protein called SUN1. ... Biology (IMB) in collaboration with their partners at the ... United States and the Institute of Cellular and System ...
... BOSTON Binkies, corks, soothers. Whatever you call pacifiers, ... interfere with breastfeeding. New research, however, challenges ... in newborn nurseries may actually increase infants, consumption of ... to be presented Monday, April 30, at the Pediatric ...
Cached Biology News:Scientists discover enzyme that could slow part of the aging process in astronauts -- and the elderly 2Scientists uncover exciting lead into premature aging and heart disease 2Researchers question pulling plug on pacifiers 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
... contains 5 ml of DETACHaBEAD Mouse CD4, ... CD4+ T cells from Dynabeads Mouse CD4 ... T cells from Dynabeads Mouse CD4 using ... suitable for any downstream application including flow ...
Porcine IFN-gamma ELISpot Development Module...
Biology Products: